FDA IND clearance for Ph 1 trial of CUR-001 in mesothelin-positive advanced refractory solid tumours October 6, 2026
Jaypirca (pirtobrutinib) receives expanded indication from US FDA for 1L CLL/SLL patients October 6, 2026
